The DOI matches its Crossref record; 274 of the 279 references it cites were found in a registry or an index; 114 of the 190 sources its claims cite were checked for support.
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Open accessAbstract
Current drug treatments have only symptomatic effects, and disease-modifying treatments are not yet available. Drug delivery to the central nervous system remains a complex process and represents a challenge.
Overview
CoChat Summary
TL;DR
This review argues that Alzheimer’s disease is a progressive, multifactorial disorder for which current drugs are only symptomatic and not curative, making prevention and earlier intervention the main priorities. It emphasizes modifiable risk factors, lipid-based prevention, and soft nanoparticles—especially liposomes and exosomes—as promising ways to improve delivery across the blood–brain barrier.
Key findings
- AD is described as a continuum with preclinical, MCI due to AD, and dementia stages; the first neuropathological signs can appear 15–20 years before disease onset.
- The paper states that more than 30% of AD cases could be due to modifiable risk factors, and cites a report identifying 12 modifiable risk factors that account for about 40% of dementias worldwide.
- Current approved AD drugs are four symptomatic medications: donepezil, memantine, galantamine, and rivastigmine; the paper says their effects are only partial and temporary.
- The review highlights soft nanoparticles as delivery tools: liposomes and exosomes are presented as capable of crossing the BBB, and intranasal administration is described as a promising route; however, no nanosystem has passed the clinical development stage for intranasal delivery.
Methods
- Narrative review of the literature on AD clinical spectrum, pathophysiology, risk factors, models, treatments, and delivery strategies.
- Synthesizes findings from human studies, clinical trials, in vitro models, animal models, and nanotechnology/drug-delivery studies cited throughout the paper.
- Main analysis is qualitative and comparative rather than experimental, organizing evidence into prevention, modeling, treatment limitations, and BBB-delivery approaches.
Limitations
- Stated by the paper: current treatment effects are symptomatic, partial, and temporary, and there is no curative treatment or disease-modifying treatment yet.
- Stated by the paper: evidence for prevention and intranasal approaches is limited by short study durations, inconsistent results, and the fact that no nanosystem has passed clinical development.
- Evident from the text: this is a broad review, so its conclusions depend on heterogeneous prior studies and do not present new primary data or a formal meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Alzheimer’s Disease spectrum. (A) Key players in the pathogenesis of Alzheimer’s disease (AD). Reprinted with permission from [12]. Copyright 2009, Nature Publishing Group. (B) Aging and metabolic diseases alteration of brain metabolism, which progressively causes AD. Reprinted from [65], Copyright 2017, Yonsei University College of Medicine. (C) Differential diagnosis of AD using neuroimaging biomarkers. Reprinted with permission [66]. Copyright 2009, Elsevier.](/paper-figures/e8086ea2fb2c44a18e66c883790856eb/alzheimer-s-disease-treatment-strategies-and-their-limitations-figure-1.jpg)
![Figure 2 3D in vitro models of Alzheimer’s disease. (A) PLGA scaffold encapsulating iPSC-derived NPCs, shown by proliferation marker Ki67, undifferentiated cell marker Nestin, and neural differentiation marker TuJ1. (i–iii) Cross-section ofthe 3D microfiber scaffold showing cell infiltration, distribution and differentiation. (iv,v) cell proliferation and differentiation. (vi) SEM image of the scaffold cross-section. Reprinted with permission from [134]. Copyright 2020, The Royal Society of Chemistry. (B) Reduction of neural plasticity in neural stem cells as a result of Aβ plaques. Image (i,iii) indicate healthy neural stem cells, which can form new synaptic connections, shown in (iii). Image (ii,iv) have the Aβ plaques incorporated in the hydrogel and are unable to form new synaptic connections. Reprinted with permission from [135]. Copyright 2018, Elsevier. (C) 3D spheroids derived from human neural progenitor cells, displaying Aβ pathology (shown in blue). Green and Red channels depict the neuronal cells and differentiated neurons, respectively. Reprinted from [138]. Copyright 2020, Nature Portfolio. (D) Acoustofluidic platform to assemble cells and Aβ oligomers into neuro-spheroids representing AD. Reproduced with permission of The Royal Society of Chemistry [139]. (i) cross-section of the 3D microfiber scaffold after sectioning (dotted line indicates the top surface of the 3D scaffold); (ii,iii) cell infiltration, distribution and differentiation of iPSC-derived NPCs (8529 cell line) inside the 3D scaffold as assessed via staining for TuJ1 (green) and Nestin (red) markers on D13; (iv) cell proliferation assessed by the Ki67 (green) marker and (v) cell differentiation with neurite formation indicated by the TuJ1 (red) marker of hESC-derived NPCs on D13; nuclei were counterstained with DAPI (blue); (vi) SEM image of the scaffold cross-section showing cell morphology and attachment on microfibers at 2000× magnification.](/paper-figures/e3a8b9b3bac94ab19d6a9627039ad12d/alzheimer-s-disease-treatment-strategies-and-their-limitations-figure-2.jpg)

Verification
Claims the paper makes
73 Valid · 2 Not valid · 37 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Research has shown that in the world, more than 30% of AD cases could be due to modifiable risk factors, which could provide interesting and promising targets for prevention strategies to reduce the risk of AD-related cognitive decline and perhaps ND in general [3,20,21].”
§ Alzheimer’s Disease: Treatment Strategies and Their Limitations > 1. Introduction
What the sources say
- Partly supportedcites [3] Livingston, 2020, Dementia Prevention, Intervention, and Care: 2020 Report of the Lancet Commission, Lancet sourceExperimental — accuracy not yet measured
The Executive summary reports that 12 modifiable risk factors account for around 40% of worldwide dementias, and “Dementia in LMIC” gives an earlier estimate of 35%, assuming causation. Those estimates concern dementia overall, not Alzheimer's disease cases specifically, so they do not establish the claim at that level of specificity. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [20] Norton, 2014, Potential for Primary Prevention of Alzheimer’s Disease: An Analysis of Population-Based Data, Lancet Neurol. source
- Partly supportedcites [21] Livingston, 2017, Dementia Prevention, Intervention, and Care, Lancet sourceExperimental — accuracy not yet measured
The Abstract says that around one third of dementia may theoretically be preventable through addressing potentially reversible risk factors. That supports the approximate proportion and prevention premise, but it refers to dementia overall, not specifically to worldwide Alzheimer's disease cases. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, nanotechnology can be used to improve the bioavailability of PUFA in the form of NL [34,37].”
§ Alzheimer’s Disease: Treatment Strategies and Their Limitations > 1. Introduction
What the sources say
- Partly supportedcites [34] Kaushik, 2018, Personalized Nanomedicine for CNS Diseases, Drug Discov. Today sourceExperimental — accuracy not yet measured
The Alzheimer’s disease section describes liposome-based nanocarriers for delivering other compounds, including curcumin. It does not say that nanoliposomes improve PUFA bioavailability; searches for PUFA, polyunsaturated fatty acids, and fatty-acid bioavailability found no such passage in our copy. (LLM, conf=0.79)
- Partly supportedcites [37] Ross, 2018, Liposome Delivery Systems for the Treatment of Alzheimer’s Disease, Int. J. Nanomed. sourceExperimental — accuracy not yet measured
The Stealth liposomes section (page unavailable) says modified liposomes can improve circulation time, supporting the general delivery-system premise. The copy does not say that nanoliposomes improve the bioavailability of PUFAs specifically; searches for PUFA, polyunsaturated fatty acids, and fatty-acid bioavailability found no such passage. (LLM, conf=0.79)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This could explain why part of the risk factors for cardiovascular disease are in common with AD, including hypertension, dyslipidemia, diabetes, obesity, dietary factors, smoking, and physical activity (Figure 1B).”
§ Alzheimer’s Disease: Treatment Strategies and Their Limitations > 2. Understanding Clinical Spectrum of AD > 2.4. Risk Factors of SAD
What the sources say
- Not checked — no full text of the sourcecites [1] Scheltens, 2016, Alzheimer’s Disease, Lancet source
- Partly supportedcites [22] Dubois, 2016, Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria, Alzheimer’s Dement. sourceExperimental — accuracy not yet measured
Section 3.4 identifies hypertension, obesity, diabetes, physical inactivity, and smoking as AD risk factors; section 3.5 discusses diet and exercise in relation to AD risk. The paper also groups cardiovascular and lifestyle factors as modifiable AD risks, but our copy does not identify dyslipidemia as an AD risk factor, so the full list is not supported. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [100] Whitmer, 2005, Midlife Cardiovascular Risk Factors and Risk of Dementia in Late Life, Neurology source
- Partly supportedcites [101] Zlokovic, 2011, Neurovascular Pathways to Neurodegeneration in Alzheimer’s Disease and Other Disorders, Nat. Rev. Neurosci. sourceExperimental — accuracy not yet measured
The Alzheimer’s disease section (page not provided) says that cerebrovascular and Alzheimer’s disease risk factors substantially overlap, and specifically names midlife diabetes, hypertension, and obesity. It does not identify dyslipidemia, dietary factors, smoking, or physical activity as shared risk factors. (LLM, conf=0.86)
- Partly supportedcites [102] Yu, 2020, Evidence-Based Prevention of Alzheimer’s Disease: Systematic Review and Meta-Analysis of 243 Observational Prospective Studies and 153 Randomised Controlled Trials, J. Neurol. Neurosurg. Psychiatry sourceExperimental — accuracy not yet measured
The Results (Figure 5) identify hypertension, diabetes, midlife obesity, physical exercise, and smoking as factors relevant to Alzheimer’s disease prevention. The passages do not establish dyslipidemia or dietary factors as Alzheimer’s disease risk factors, so they do not support the full list of shared cardiovascular and Alzheimer’s risk factors. (LLM, conf=0.85)
- Partly supportedcites [103] Edwards, 2019, Modifiable Risk Factors for Alzheimer’s Disease, Front. Aging Neurosci. sourceExperimental — accuracy not yet measured
The Vascular Diseases section (page unavailable) explicitly identifies hypertension, diabetes, and hypercholesterolemia as risks shared by cardiovascular disease and AD; its Smoking section also links smoking to cardiovascular disease and dementia. The paper discusses diet and obesity in relation to diabetes and AD, but does not establish every item in the citing sentence as a shared cardiovascular–AD risk factor. Its Physical Activity section says it remains unknown whether exercise reduces the risk of developing AD. (LLM, conf=0.86)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The main risk factor for SAD is age. Indeed, increased life expectancy is correlated with a higher probability of developing neurodegenerative diseases, including AD [89,90].”
§ Alzheimer’s Disease: Treatment Strategies and Their Limitations > 2. Understanding Clinical Spectrum of AD > 2.4. Risk Factors of SAD
What the sources say
- Supportedcites [89] Hebert, 2010, Change in Risk of Alzheimer Disease over Time, Neurology source
The Discussion (p. 790) calls age an “extremely important predictor of AD risk,” supporting the claim that age is a principal risk factor. The paper studies AD in a community population rather than separately identifying sporadic cases, but the citing sentence makes a broad background point, not a subtype-specific estimate. (LLM, conf=0.86)
- Not matchedcites [90] Prince, M.J., Guerchet, M.M., and Prina, M. (2022, June 04). The Epidemiology and Impact of Dementia: Current State and Future Trends. WHO Thematic Briefing. Available online: https://hal.archives-ouvertes.fr/hal-03517019.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Soft NP, such as nanoliposomes (NL) or exosomes, represent one of the most effective drug delivery processes to be able to protect therapeutic agents and deliver them to the target tissues [32,33].”
§ Alzheimer’s Disease: Treatment Strategies and Their Limitations > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [32] Agrawal, 2017, Recent Advancements in Liposomes Targeting Strategies to Cross Blood-Brain Barrier (BBB) for the Treatment of Alzheimer’s Disease, J. Control. Release source
- Partly supportedcites [33] Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., and Karamanos, Y. (2020). Targeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles. Cells, 9. sourceExperimental — accuracy not yet measured
The Introduction says lipid-based nanoparticles can enclose and protect therapeutic compounds and be designed to target the brain. Section 4 describes exosomes delivering therapeutic cargo to the brain. The paper does not establish that nanoliposomes and exosomes are among the most effective delivery methods, or address delivery to target tissues generally. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
68 more claims · 31 with their cited sources checked
Create a free account to see all 157 claims and to verify the 3 references still open.
- It may state two separate claims as one. 73
- Probably not a substantial claim. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It becomes a comprehensive care paradigm when pharmacological therapies are combined with lifestyle changes, cognitive training, and psychosocial support.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [221]
Experimental — accuracy not yet measuredIn the citing paper
“This approach is adaptable enough to be customized for every single patient, ensuring optimal treatment outcomes [220,221].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [221]
In the citing paper
“These drugs are used for all stages of AD, but inhibition of cholinesterase enzymes works best at the early stage of AD [9, 12].”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [9]
In the citing paper
“Current therapeutics to ameliorate and control the cognitive and behavioral symptoms by targeting the NMDA receptor prevent Ca2+ induced excitotoxicity [2, 9–11], and memantine was approved for this purpose in 2003.”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [9]
In the citing paper
“Memantine is more effective in providing cognitive and behavioral benefits and approved for patients with moderate to severe AD as monotherapy or combination therapy with donepezil [9, 12].”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [9]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“A history of head trauma and hearing loss may favor the onset of AD [3,102,116].”
Cited work 10.1016/s0140-6736(20)30367-6 · retracted 2023-05-01 · notice 10.1016/s2468-2667(23)00083-x · this paper published 2022-11-12
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 5×
“A history of head trauma and hearing loss may favor the onset of AD [3,102,116].”
BackgroundInfluentialRetractedDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“The NFT then evolves in the external part of the temporal lobe before spreading to the posterior cortical associative areas and the entire cortex [6].”
BackgroundNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · cited 6×
“The presence of biomarkers can be used to indicate the severity of the AD [7,71]: decreased CSF Aβ levels, increased CSF Tau and/or P-Tau levels, cortical thinning and hippocampal atrophy based on MRI, hypometabolism or hypoperfusion of posterior cingulate and temporoparietal cortex (FDG-PET), and detection of cortica…”
InfluentialAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“The hypothesis of the amyloid cascade suggests that the anomalous accumulation of Aβ peptide and formation of amyloid plaques induce NFT formation and makes neurons more sensitive to neurotoxic effects and neuronal death [57].”
BackgroundDementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · cited 1×
“Research has shown that in the world, more than 30% of AD cases could be due to modifiable risk factors, which could provide interesting and promising targets for prevention strategies to reduce the risk of AD-related cognitive decline and perhaps ND in general [3,20,21].”
Background
Research works printed but not linked: 1
- Prince, M.J., Guerchet, M.M., and Prina, M. (2022, June 04). The Epidemiology and Impact of Dementia: Current State and Future Trends. WHO Thematic Briefing. Available online: https://hal.archives-ouvertes.fr/hal-03517019.
Cited by
Kale, M., Wankhede, N., Pawar, R., Ballal, S., Kumawat, R., Goswami, M., Khalid, M., Taksande, B., Upaganlawar, A., Umekar, M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102497 · Cited by 183
Su, W.-M., Gu, X.-J., Dou, M., Duan, Q.-Q., Jiang, Z., Yin, K.-F., Cai, W.-C., Cao, B., Wang, Y., & Chen, Y.-P. (2023) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331142 · Cited by 161
Amyloid Precursor Protein and Alzheimer’s Disease
Orobets, K. S., & Karamyshev, A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914794 · Cited by 141
“It is predicted that a dramatic elevation of AD pathology will occur in the future, with 13.85 million Americans affected by Alzheimer’s dementia and 152 million affected around the world by the year 2050 [2,3].”
InfluentialBeltrán-Velasco, A. I., & Clemente‐Suárez, V. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062440 · Cited by 135
“There are significant unmet needs in the effective modulation of neuroinflammation and BBB dysfunction, particularly in the context of systemic inflammatory responses [97].”
Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders
Cohen, J., Mathew, A., Dourvetakis, K. D., Sanchez-Guerrero, E., Pangeni, R. P., Gurusamy, N., Aenlle, K. K., Ravindran, G., Twahir, A., Isler, D., et al. (2024) · Cells · doi:10.3390/cells13060511 · Cited by 103
“Cholinesterase inhibitors work by increasing the neurotransmitter acetylcholine (Ach) in the brain to address the deficiency in AD patients and thus help in the transmission of information between neurons [4].”
BackgroundInfluential
Metadata
- Authors
- Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E.
- Affiliations
- Laboratoire Animal et Agroécosystèmes (FR)
- Laboratoire d'Ingénierie des Biomolécules (FR)
- University of Twente (NL)
- UConn Health (US)
- LIBio Laboratory, University of Lorraine, 54505 Vandoeuvre-lès-Nancy, France
- Corresponding author
- Yen, Frances T.
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-11-12
- Volume
- 23
- Issue
- 22
- Pages
- 13954
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9697769
- OpenAlex
- W4309008621
- Semantic Scholar
- 9dbe6b562aec1dc05309ecc0b7a89b81e6fd01bf
- Cited by
- 689
- References
- 279
- Citations by year
- 2026: 204 · 2025: 255 · 2024: 171 · 2023: 58 · 2022: 1
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Twente Research Information (publishedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Twente Research Information (submittedVersion, cc-by)
- Funders
- Agence Nationale de la Recherche (ANR-15-IDEX-0004)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, Alzheimer's disease prevention, risk factors, disease-modifying therapy, brain drug delivery, blood-brain barrier, nanoliposomes, exosomes, nanoparticles, intranasal administration
- MeSH terms
- Alzheimer Disease, Blood-Brain Barrier, Humans, Drug Delivery Systems, Neurodegenerative Diseases, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alzheimer's Disease: Treatment Strategies and Their Limitations. https://app.cochat.ai/papers/10.3390/ijms232213954
- The paper
- Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022). Alzheimer's Disease: Treatment Strategies and Their Limitations. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms232213954
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.